Roundview Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Roundview Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.16M	Buy	40,408 +10,321	+34%	+$1.29M	0.32%	74
2025 Q4	$3.67M	Buy	30,087 +25,607	+572%	+$2.94M	0.23%	98
2025 Q3	$449K	Buy	+4,480	New	+$404K	0.03%	272
2024 Q4	–	Sell	-13,047	Closed	-$1.29M	–	346
2024 Q3	$1.29M	Buy	+13,047	New	+$1.28M	0.09%	189
2023 Q3	–	Sell	-15,126	Closed	-$1.26M	–	318
2023 Q2	$1.26M	Sell	15,126 -2,109	-12%	-$176K	0.12%	166
2023 Q1	$1.31M	Buy	17,235 +2,106	+14%	+$175K	0.14%	158
2022 Q4	$1.26M	Buy	15,129 +3,156	+26%	+$256K	0.14%	155
2022 Q3	$950K	Buy	11,973 +1,757	+17%	+$148K	0.12%	164
2022 Q2	$759K	Buy	10,216 +2,617	+34%	+$196K	0.09%	192
2022 Q1	$683K	Buy	7,599 +5,575	+275%	+$515K	0.07%	210
2021 Q4	$227K	Buy	+2,024	New	+$244K	0.02%	283

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Roundview Capital's XBI Position: Q1 2026 in Review

Roundview Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 34% in Q1 2026, buying an estimated $1.29M and bringing the position to 40,408 shares worth $5.16M. The position accounts for 0.32% of the portfolio, ranked #74.

Roundview Capital first reported a position in XBI in Q4 2021 and has held it in 11 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Roundview Capital held 40,408 shares of State Street SPDR S&P Biotech ETF worth $5.16M as of Q1 2026.
Roundview Capital bought 10,321 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.29M.
State Street SPDR S&P Biotech ETF made up 0.32% of Roundview Capital's portfolio in Q1 2026, its #74 holding.
Roundview Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 11 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Roundview Capital's 13F filing for Q1 2026, filed 8 May 2026.